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Abstract
Aims: Radiotherapy is an important treatment modality in the multidisciplinary management of rectal cancer. It is delivered both in the neoadjuvant setting and
postoperatively, but, although it reduces local recurrence, it does not inﬂuence overall survival and increases the risk of long-term complications. This has led to
a variety of international practice patterns. These variations can have a signiﬁcant effect on commissioning, but also future clinical research. This study explores
its use within the large English National Health Service (NHS).
Materials and methods: Information on all individuals diagnosed with a surgically treated rectal cancer between April 2009 and December 2010 were extracted
from the Radiotherapy Dataset linked to the National Cancer Data Repository. Individuals were grouped into those receiving no radiotherapy, short-course
radiotherapy with immediate surgery (SCRT-I), short-course radiotherapy with delayed surgery (SCRT-D), long-course chemoradiotherapy (LCCRT), other
radiotherapy (ORT) and postoperative radiotherapy (PORT). Patterns of use were then investigated.
Results: The study consisted of 9201 individuals; 4585 (49.3%) received some form of radiotherapy. SCRT-I was used in 12.1%, SCRT-D in 1.2%, LCCRT in 29.5%,
ORT in 4.7% and PORT in 2.3%. Radiotherapy was used more commonly in men and in those receiving an abdominoperineal excision and less commonly in the
elderly and those with comorbidity. Signiﬁcant and substantial variations were also seen in its use across all the multidisciplinary teams managing this disease.
Conclusion: Despite the same evidence base, wide variation exists in both the use of and type of radiotherapy delivered in the management of rectal cancer
across the English NHS. Prospective population-based collection of local recurrence and patient-reported early and late toxicity information is required to
further improve patient selection for preoperative radiotherapy.
 2016 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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Radiotherapy is an established treatment modality in the
multidisciplinary management of rectal cancer. In the
1990s, phase III trials reported reduced local recurrence and
improved overall survival using a combination of post-
operative chemotherapy and concurrent chemoradiation
(CRT). Subsequently, randomised trials, mainly in Europe,
showed a reduction in local recurrence with the preopera-
tive addition of either a 1 week short course of radiotherapy
or the addition of concurrent chemotherapy to a 5 week
course of preoperative radiotherapy [1].
Two recently reported phase III trials have conﬁrmed a
halving of the rate of local recurrence when a 1 week short
course of radiotherapy was added to surgical resection [2,3].
Two phase III trials reported reduced local recurrence when
preoperative CRT was compared with long-course radio-
therapy alone [4,5]. Local recurrence, acute and late toxicity
were reduced when preoperative CRT was compared with
postoperative CRT [6,7]. The combined results led to amajor
shift towards the use of preoperative radiotherapy in the
form of short-course and CRT schedules. In parallel,
improved surgical technique using total mesorectal excision
led to low reported rates of local recurrence with surgery
alone [8]. This ﬁnding was conﬁrmed in the Medical
ResearchCouncil CR07 trial,where thebest planesof surgical
excision resulted in the lowest rates of local recurrence [9].
Although preoperative radiotherapy can reduce the risk
of local recurrence, it can also increase the risk of long-term
side-effects when added to surgical resection [10e13].
These long-term side-effects seem to be similar whether
preoperative short-course radiotherapy or CRT is used
[14,15].
In the National Health Service (NHS) of England, weekly
multidisciplinary team (MDT)meetings take place to review
the clinical and radiological staging of all rectal cancer pa-
tients. Pelvic magnetic resonance imaging (MRI) is routinely
used to determine the use of preoperative and postoperative
radiotherapy in management, further increasing the
complexity of decision making. International evidence sug-
gests thereissigniﬁcantvariationintheuseofradiotherapyin
themanagementof rectal cancer [16e20], but, unlike theUK,
many countries do not routinely use MRI for pelvic staging,
which may explain in part the variation observed. Little is
known about the patterns of radiotherapy use in England.
This study explored the use of radiotherapy in surgically
treated rectal cancer at a population level using the ﬁrst
available data from the national Radiotherapy Dataset
(RTDS) [21]. These data are extracted and collated from all
NHS linear accelerators. When combined with the infor-
mation in the National Cancer Data Repository (NCDR) [22]
these data enable patterns of management to be investi-
gated [23e25] across the English NHS.Materials and Methods
All individuals diagnosed with a ﬁrst primary rectal
cancer between 1 April 2009 and 31 December 2010 andwho underwent a major resection for the disease within the
English NHS were identiﬁed (using standard algorithms)
[24,26] within the linked cancer registry and Hospital
Episode Statistics (HES) component of the NCDR [22].
Information on age, gender, Dukes’ stage of disease at
diagnosis, tumour site, socioeconomic status (based on In-
dex of Multiple Deprivation (IMD) income quintile) and
survival were taken from the cancer registry component of
the resource, whereas information on the type of surgery
and hospital MDT of surgical management was taken from
the HES component. A Charlson comorbidity score [27] was
also derived for each individual based on the diagnostic
reasons (excluding cancer) for any hospital admissions
recorded in HES in the year before diagnosis (excluding any
admission spanning the date of diagnosis). The cancer
component of the score was then derived from the cancer
registry information and combined with the hospital
admission scores. Higher scores indicate greater comorbid
disease and patients were grouped into Charlson score
categories of 0, 1, 2 and 3.
To investigate patterns of use of radiotherapy, any
records for this cohort of individuals within the RTDS (now
also available in the NCDR) were identiﬁed. The RTDS
contains information on every episode of radiotherapy
delivered, but the dataset does not consistently capture
whether the intent of the dose delivered was adjuvant,
radical or palliative. In addition, the disease coding within
the resources varies between centres and total attendances
are captured rather than intended fractionation patterns.
An individual may also have multiple summary RTDS
records that overlap the same time period and seem to
relate to the same episode of radiotherapy being delivered.
An algorithm was therefore developed to identify neo-
adjuvant or adjuvant treatment records from the resource
among all other episodes of radiotherapy administered to
this rectal cancer population. First, only episodes of radio-
therapy that the RTDS stated had been used to treat colo-
rectal (ICD10 [28] C18-20), anal (C21) or an unspeciﬁed
digestive cancer (C78, C80, D01 and D37) and occurred
within a year of the date of surgery for each individual in the
cohort were deemed eligible. If individuals had multiple
episodes of radiotherapy delivered in overlapping time
periods then the episode that recorded the highest number
of attendances was retained, but the individual was ﬂagged
so that these multiple episodes were acknowledged.
Individuals were then allocated to one of ﬁve groups based
on the standard rectal radiotherapy regimens used in
England and the total number of attendances they made to
a radiotherapy centre. Those for whom there was no link to
the RTDS were deemed to have received no neoadjuvant or
adjuvant radiotherapy. Those who had attended a radio-
therapy centre ﬁve times before surgery and for whom the
time between the start of radiotherapy and surgery was 35
days or less were allocated to a short-course radiotherapy
and immediate surgery category (SCRT-I). Those meeting
the same attendance criteria, but where the interval
between radiotherapy and surgery was greater than 35
days, were allocated to the short-course radiotherapy and
delayed surgery category (SCRT-D). Those who attended for
Table 1
Characteristics of the study population
Characteristic NRT SCRT-I SCRT-D LCCRT Other PORT Any radiotherapy Total
n % n % n % n % n % n %
Age group 60 929 39.6 282 12.0 15 0.6 951 40.5 109 4.6 63 2.7 1420 60.5 2348
61e70 1484 48.6 377 12.3 27 0.9 933 30.5 166 5.4 71 2.3 1574 51.5 3056
71e80 1509 53.3 362 12.8 40 1.4 731 25.8 129 4.6 61 2.2 1323 46.7 2832
>80 694 71.9 94 9.7 28 2.9 98 10.2 31 3.2 20 2.1 271 28.1 965
Gender Male 2889 48.2 773 12.9 69 1.2 1849 30.8 276 4.6 138 2.3 3105 51.8 5994
Female 1727 53.9 340 10.6 41 1.3 864 26.9 159 5.0 76 2.4 1480 46.1 3207
Dukes stage at diagnosis A 1289 64.7 253 12.7 13 0.7 345 17.3 76 3.8 17 0.9 704 35.3 1993
B 1239 54.7 282 12.5 31 1.4 559 24.7 107 4.7 46 2.0 1025 45.3 2264
C 1441 45.5 375 11.8 32 1.0 1057 33.4 164 5.2 97 3.1 1725 54.5 3166
D 299 50.1 39 6.5 9 1.5 191 32.0 34 5.7 25 4.2 298 49.9 597
Unknown 348 29.5 164 13.9 25 2.1 561 47.5 54 4.6 29 2.5 833 70.5 1181
Charlson comorbidity score 0 3645 48.1 957 12.6 91 1.2 2349 31.0 355 4.7 176 2.3 3928 51.9 7573
1 655 57.8 111 9.8 12 1.1 268 23.7 63 5.6 24 2.1 478 42.2 1133
2 204 60.4 32 9.5 5 1.5 72 21.3 14 4.1 11 3.3 134 39.6 338
3 112 71.3 13 8.3 2 1.3 24 15.3 3 1.9 3 1.9 45 28.7 157
IMD income category Most afﬂuent 1072 53.2 226 11.2 19 0.9 542 26.9 109 5.4 46 2.3 942 46.8 2014
2 1115 51.9 279 13.0 20 0.9 622 29.0 74 3.4 37 1.7 1032 48.1 2147
3 995 50.4 241 12.2 21 1.1 577 29.2 92 4.7 49 2.5 980 49.6 1975
4 816 48.2 212 12.5 28 1.7 521 30.8 70 4.1 46 2.7 877 51.8 1693
Least afﬂuent 618 45.0 155 11.3 22 1.6 451 32.9 90 6.6 36 2.6 754 55.0 1372
Operation type APE 550 25.4 334 15.4 45 2.1 1049 48.4 160 7.4 31 1.4 1619 74.6 2169
AR 3191 57.9 662 12.0 44 0.8 1312 23.8 214 3.9 90 1.6 2322 42.1 5513
Hartmanns 407 54.1 62 8.2 14 1.9 195 25.9 38 5.1 36 4.8 345 45.9 752
Other 468 61.0 55 7.2 7 0.9 157 20.5 23 3.0 57 7.4 299 39.0 767
Total 4616 50.2 1113 12.1 110 1.2 2713 29.5 435 4.7 214 2.3 4585 49.8 9201
NRT, no radiotherapy; SCRT-I, short-course radiotherapy with immediate surgery; SCRT-D, short-course radiotherapy with delayed sur-
gery; LCCRT, long-course chemoradiotherapy; ORT, other radiotherapy; PORT, postoperative radiotherapy; IMD, index of multiple depri-
vation; APE, abdominoperineal excision; AR, anterior resection.
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undergone long-course chemoradiotherapy (LCCRT). In
addition, those who had multiple radiotherapy records in
the RTDS spanning the same time period where the
maximum attendance in one of those records was 10 or
more (but the addition of attendances in the other relevant
records would exceed 25 attendances) were also allocated
to LCCRT. Individuals who had attended for radiotherapy at
a frequency different to these standard rectal fraction
patterns were allocated to an ‘other’ radiotherapy category
(ORT). Finally, individuals who received radiotherapy up to
a year after their surgery were categorised in the post-
operative radiotherapy (PORT) group.
Patterns of use of radiotherapy in rectal cancer were then
investigated in relation to both the characteristics of the
patients, their tumours, the interval to surgery and their
management. The statistical signiﬁcance of any differences
in the type of radiotherapy used was assessed using the chi-
squared test.
The work was given ethical approval by the East of
Scotland Research Ethics Service (LR/08/S0501/66).Results
In total, 9201 individuals were identiﬁed within the
NCDR as having undergone major resection for a ﬁrstprimary rectal cancer diagnosed in the study period. Over-
all, 4616 (50.2%) of this population did not receive any
radiotherapy in the management of their primary disease.
By contrast, 1113 (12.1%) received SCRT-I, 110 (1.2%) SCRT-D,
2713 (29.5%) LCCRT, 435 (4.7%) ORT and 214 (2.3%) PORT.
The characteristics of the population in relation to their
treatment group are shown in Table 1. The use of radio-
therapy decreased with age, with 60.5% of those less than
60 years of age at diagnosis receiving some form of radio-
therapy compared with 28.1% of those aged over 80 years.
Radiotherapy was also used more frequently in men than
women (51.8% versus 46.1%). The use of radiotherapy
increased with increasing stage (35.3% in Dukes A versus
54.5% in Dukes C) and also increased in relation to
increasing socioeconomic deprivation, with 46.8% of those
residing in the most afﬂuent areas receiving the treatment
compared with 55.0% in the least afﬂuent areas. By contrast,
rates of use of radiotherapy decreased in relation to
increasing comorbidity, being used in 51.9% of those with a
Charlson score of 0 compared with 28.7% of those with a
score of 3 ormore. Some form of radiotherapywas also used
more frequently in those undergoing abdominoperineal
resection compared with other types of major resection.
Signiﬁcant variation in the use of the different modalities
of radiotherapy for the management of rectal cancer was
seen across English NHS Trusts (Figure 1). The proportion of
individuals in each Trust who did not receive any
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there were signiﬁcant differences in the deployment of the
different types of radiotherapy,with SCRT-I use ranging from
0.0% to 40.2%, SCRT-D from 0.0% to 10.0% and LCCRT from
5.1% to 62.5%. A few Trusts also seemed to apply a relatively
high number of non-standard regimens,with the proportion
of people in theORTcategory rangingacross Trusts from0.0%
to 52.8%. Twenty-three Trusts used a non-standard regimen
in more than 10% of their cases. PORT was used infrequently
in all Trusts, with a maximum use of 11.1%.
A signiﬁcant, although slightly less marked variationwas
observed across the larger aggregation of MDTs within the
English NHS’s Local Area Teams (Figure 2). The proportion
of individuals across the Local Area Teams who did not
receive any radiotherapy ranged between 27.8% and 66.1%,
but, as previously, there was also signiﬁcant variation in the
types of radiotherapy delivered. The proportion receiving
SCRT-I ranged between 0.4% and 19.3%, SCRT-D between
0.0% and 3.4%, LCCRT between 18.1% and 50.5%, PORT
between 0.4% and 4.1% and ORT between 1.1% and 29.6%.
Therewas also signiﬁcant variation in practice in relation
to the interval between the start of radiotherapy and sur-
gery. Figure 3 shows the distribution in the number of days
for this interval for individuals undergoing some form of
SCRT. Most of the population who underwent SCRT-I
surgery were resected within 14 days of the start of their
radiotherapy, with a median interval of 9 days (interquartile
range 8e11). There was, however, a considerable range inFig 1. The proportion of individuals with surgically resected rectal canc
disciplinary teams in the English National Health Service.practice, with 113 people having 35 days or more between
the start of radiotherapy and surgery (i.e. SCRT-D) and 34
people having an interval of 100 days or more. The median
interval for this SCRT-D group was 72 days (interquartile
range 52e118). The variation was also signiﬁcant in the
LCCRT group (Figure 4), with the interval between the start
of radiotherapy and surgery ranging from 42 to 335 days.
The median in the LCCRT category was 113 days (inter-
quartile range 98e133). Figure 5 shows the distribution of
the 435 people in the ORT category in relation to both the
interval between radiotherapy and surgery and the total
number of attendances to hospital. Most of the cases in this
group arose from individuals attending hospital four or
fewer times and receiving their subsequent surgery within
35 days of the ﬁrst attendance. A further 253 individuals
had intervals of greater than 35 days from the start of their
radiotherapy to surgery and most of this group had greater
than ﬁve attendances.Discussion
This retrospective population-based study is the ﬁrst to
provide a comprehensive national perspective on the use of
radiotherapy in the management of surgically treated rectal
cancer patients across England. Overall, 49.8% of the
population received some form of radiotherapy, but there
was variation across the population, with radiotherapy useder in each of the radiotherapy categories across all colorectal multi-
Fig 2. The proportion of individuals with surgically resected rectal cancer in each of the radiotherapy categories across all the Local Area Teams
of the English National Health Service.
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noperineal resection and less commonly in the elderly and
those with comorbid disease. Signiﬁcant variation in prac-
tice was also observed across the English NHS, irrespective
of patient case mix, with regards to both the type of
radiotherapy used and the interval between its initiation
and surgery.
These data can be compared with those in the National
Bowel Cancer Audit Project [29]. This voluntary audit
captures data on around 86% of colorectal cancer patients
treated in the UK, but its prime focus is surgery and only
limited information is available within it on the use of
radiotherapy. In the 2012 report (based on cases diagnosed
in 2010/11), radiotherapy was used in a lower proportion of
rectal cancer cases than in this study (41.7% versus 49.3%),
with short course being used in 14.8% of cases, long course
in 24.2% and postoperative in 1.7%. Radiotherapy was not
reported or not given in 59.4% of cases. The data analysis
cannot discriminate between these two responses. The
audit indicated variation between Trusts (rates of use varied
between 0 and 93%), but because of the voluntary nature of
the audit and the lack of clarity of whether the treatment
was not given or simply not reported it is hard to draw any
ﬁrm conclusions. Signiﬁcant variation in practice has also
been observed across Welsh colorectal MDTs [30]. The
current study provides, on a much larger sample, more
robust population-based data for England and conﬁrms
signiﬁcant variation in national patterns of practice.This study not only showed variation in whether radio-
therapy was used but also in what type was delivered and
how long the interval was between the start of the radiation
and surgery. To our knowledge no data have previously
been published quantifying the extent of this variation
across the English NHS. All these observed variations in
radiotherapy usage were seen despite the routine weekly
colorectal MDT meetings, which occur across the NHS, in
which clinical and radiological staging investigations,
including pelvic MRI, are reviewed to determine the selec-
tion of patients for preoperative treatment. MDTs are,
therefore, adopting very different treatment strategies.
How can this wide variation in radiotherapy usage be
explained? A number of factors may have inﬂuenced MDT
decisions. First, the Colorectal Improving Outcomes Guid-
ance from 2004 [31] (which would have been relevant to
the period covered by this study) recommended the use of
either short-course preoperative radiotherapy or initial
surgery with selective use of postoperative CRT based on
involvement of the circumferential resection margin
according to each MDT’s deﬁned unit policy. Only a
minority of patients who undergo initial surgery will have
an involved circumferential resection margin.
Second, there has been a growing body of evidence that
preoperative radiotherapy lowers the risk of rectal cancer
recurrence without any measurable impact on overall
survival in moderate risk disease accompanied by lower
rates of local recurrence with total mesorectal excision
Fig 3. The number of individuals attending hospital for short-course radiotherapy in relation to the interval between the start of radiotherapy
and surgery.
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probably also relevant, with a correlation existing between
lower local recurrence rates with better planes of surgical
excision [9]. Finally there was also increasing concern that
the addition of preoperative radiotherapy may lead to
increased long-term toxicity [10,11,32,33]. The weight each
MDT placed on these different factors may account for the
variability in practice observed.
Further evidence has been published relevant to the
optimal use of radiotherapy in rectal cancer management
subsequent to the study period. For example, several rele-
vant phase III trials reported their outcomes after 2004 and
new National Institute for Health and Care Excellence
(NICE) colorectal cancer guidelines incorporating their
ﬁndings were published in 2011 [34]. These guidelines
deﬁne three risk groups for local recurrence after rectal
cancer resection based on the pelvic MRI ﬁndings. Surgery
alone is recommended for the low-risk group. SCRT or
LCCRT should be considered for the medium-risk group and
LCCRT for the high-risk group.
Several international studies have investigated the vari-
ation in use of radiotherapy for rectal cancer
[16,18e20,35e38]. Van Leersum et al. [38] reported a
population-based study from the Netherlands between
2009 and 2011 and found that 85% of patients received
preoperative radiotherapy. This is a signiﬁcantly greater
proportion than these English data indicate, but theNetherlands guidelines recommend the use of preoperative
radiotherapy for all patients except those with T1N0
disease. By contrast, the recently published European
Society of Medical Oncology rectal cancer radiotherapy
guidelines [39] recommend a similar approach to those
published by NICE in 2011 [34].
The signiﬁcant variation in the range of intervals
between the start of radiation and surgery is also of interest.
The evidence based around what constitutes the optimal
interval in either SCRT or LCCRT is relatively weak [39e42]
and it seems that, in the absence of deﬁnitive data, the
practice patterns of MDT’s are divergent. This may be
further exempliﬁed by the unusual spread of attendance
patterns in the ORT group. A high proportion of this cate-
gory attended hospital four times, suggesting the use of a
four-fraction protocol. Although such a regimen is not
widely used, the northwest rectal cancer randomised trial
showed a signiﬁcant reduction in local recurrence with
20 Gy in four fractions [43]. Alternatively, the unusual
attendance patterns observed may indicate the use of
different fractionation regimens or that patients
discontinued treatment due to the toxicity of other medical
events. These data cannot currently provide the detailed
information to determine the cause or causes.
Indeed, a signiﬁcant limitation of this study was the
quality and extent of the data available in the RTDS.
Numerous weaknesses were identiﬁed, including poor
Fig 4. The number of individuals attending hospital for long-course chemoradiotherapy in relation to the interval between the start of
radiotherapy and surgery and the total number of attendances.
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information on treatment intent and, in certain centres,
multiple episodes of care for a single course of treatment.
However, linkage of the RTDS to other data sources available
in the NCDR (notably cancer registry and HES data) along-
side detailed clinical review and analysis did enable courses
of radiotherapy to be related to both deﬁnitive diagnoses
and surgical information. Patterns of care could then be
quantiﬁed. A future development of the RTDS should,
however, seek to both extend the data scope and its quality
so that such robust analyses assessing the effect of variation
in the time between radiotherapy and surgery initiation can
be quantiﬁed and guidance produced to deﬁne optimal
practice.
Recent changes in clinical practice may also alter future
radiotherapy uptake [44]. This includes an increasing use of
extra-levator abdominoperineal excision [45] with its
reported reduced risks of resectionmargin involvement and
specimen perforation, which may in turn reduce the use of
preoperative radiotherapy. Conversely, the watch and wait
option [46] using deﬁnitive CRT without surgery, attempt-
ing to delay or avoid major surgical resection for selected
patients may be chosen by some MDTs [47]. This latter
approach is not supported, however, by the 2011 NICE
guidelines [34] and its evidence base remains inconclusive
[48]. Analysis of further NCDR data to investigate howpatterns of radiotherapy use change over time are, there-
fore, intended.
Although the present study has shown signiﬁcant vari-
ation in the use of radiotherapy, it is unable to determine
what inﬂuence this is having on locoregional failure or
patient-reported outcomes. What is the correct balance
between the beneﬁts and risks of preoperative radio-
therapy? Randomised trial evidence suggests that radio-
therapy may reduce the risk of local recurrence, but it does
not inﬂuence long-term survival. However, the addition of
radiotherapy increases long-term side-effects [32,33,49,50].
Without further information, quantifying both these posi-
tive and negative consequences of radiotherapy use, it is
impossible to assess the effect of the variation in radio-
therapy usage on patients or the NHS and this may increase
rather than minimise variation in practice.
Although MDTs now routinely collect considerable in-
formation on the process of treatment, including histo-
pathological assessment of the resected specimen, there is
no systematic and prospective approach to record the
timing and pattern of failure after rectal cancer resection
and patient-reported outcomes. Extending the capture of
such robust data to enable population-based assessment of
the true effect of treatment variation on patient outcomes
is vital if the NHS is to offer the best possible service. Our
approach will be used to monitor the inﬂuence of the 2011
Fig 5. The number of individuals attending hospital for a non-standard radiotherapy regimen in relation to the interval between the start of
radiotherapy and surgery and the number of attendances made.
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tions for the use of preoperative radiotherapy in future
guidelines will depend on robust data linkage of radio-
therapy data to both validated patient-reported outcomes
and local recurrence rates. Additional linkage to fully
completed Royal College of Radiologists and Pathologists
minimum reporting datasets for each tumour would also
give further insights to the choices made at MDT meetings.Conclusion
This population-based study has shown a wide variation
in both the use of radiotherapy and radiotherapy schedules
across the English NHS. Prospective population-based
collection of locoregional recurrence, patient-reported
toxicity and radiology and pathology datasets is required
to understand and improve patient selection for preopera-
tive radiotherapy, reduce variation in treatment and
improve outcomes.
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